Intravitreal Bevacizumab for the Treatment of Chronic or Recurrent Central Serous Chorioretinopathy

• 作者: Gerardo García Aguirre Hugo Quiroz Mercado Jans Fromow Guerra Maximiliano Gordon Angelozzi Michael D. Ober Mitzy E. Torres Soriano Veronica Kon Jara
• 来源期刊: 眼科学期刊(英文)
• 学科: 医学
• 关键词: Central SEROUS CHORIORETINOPATHY INTRAVITREAL BEVACIZUMAB Retinal Pigment EPITHELIUM DETACHMENT
• 年，卷（期）: 2014,（3）
• 页码范围: 57-64
• 页数: 8页
• 分类号: R77

摘要

Background: We report the use of intravitreal bevacizumab as an option for the treatment of chronic or recurrent central serous chorioretinopathy (CSC). Methods: Eight eyes with chronic or recurrent CSC received intravitreal bevacizumab (1.25 mg/0.05 cc) and underwent best corrected visual acuity (VA), optical coherent tomography (OCT), fluorescein angiography (FA) and indocyanine green angiography (ICG) before, and one, three and six months after treatment. Results: All patients showed improvement in visual acuity, fluorescein angiographic leakage, choroidal hyperpermeability and reduced or resolved neurosensory detachment following treatment. Two patients require a second dose of intravitreal bevacizumab. Conclusions: Intravitreal injection of bevacizumab was associated with visual improvement and reduced neurosensory detachment without adverse events in patients with chronic or recurrent CSC. Although these results are promising, further investigations would be helpful to understand this therapy for patients with CSC.